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Activation of innate immunity is associated with the development of liver disease, including non-alcoholic fatty liver disease
(NAFLD). In the innate immune system, Toll-like receptors (TLRs) are sensors that recognize bacterial and viral components
such as lipopolysaccharide, bacterial DNA, and peptidoglycan. Recent data have demonstrated that the liver is exposed to a high
load of TLR ligands due to bacterial overgrowth and increased intestinal permeability in NAFLD. Upon stimulation by these TLR
ligands, hepatic immune cells produce various mediators that are involved in host defense. On the other hand, these mediators
alter lipid metabolism, insulin signaling,and cell survival. Indeed, some TLR-deﬁcient mice demonstrate lesser degrees of NAFLD
even though TLR ligands are increased. This paper will highlight the recent progress on the study of TLR signaling and their
downstream molecules in the development of NAFLD.
1.Introduction
Nonalcoholic steatosis is a component of metabolic syn-
drome, and obese people with insulin resistance frequently
have fatty liver disease [1]. Although steatosis is considered
a benign liver disease, a subset of steatosis includes a
progressive liverdisease, nonalcohol steatohepatitis (NASH),
that causes liver cirrhosis and cancer. In 1980, Ludwig et
al. proposed the concept of “NASH”, steatohepatitis without
a history of excess alcohol intake [2]. Currently, the term
“nonalcoholic fatty liver disease (NAFLD)” is more widely
used because it isdiﬃcult todiagnose NASHatan early stage
without histological examinations. Thus, NAFLD comprises
a spectrum of disorders ranging from simple steatosis to
advanced steatohepatitis and ﬁbrosis. Since NAFLD has
become the most common liver disease and the prevalence
is estimated to be 14–24% of the population in developed
countries [3–5], NAFLD is a growing public health concern
worldwide.
Hepatic steatosis occurs when the amount of imported
and synthesized lipids exceeds the export or catabolism
in hepatocytes [6–8], including (1) increased lipid delivery
to the liver, (2) increased lipid uptake in hepatocytes, (3)
increased de novo lipogenesis in the liver, (4) failure of
lipid export, and (5) impaired hepatic mitochondrial β-
oxidation of fatty acids. Steatosis is present in most patients
with insulin resistance, suggestingthatdysfunction ofinsulin
signaling is closely associated with excessive accumulation
of lipid in the liver. However, hepatic inﬂammation and
consequent ﬁbrosis are not always observedin these patients,
suggesting that additional factors are required for the
development of NASH.
This paper highlights Toll-like receptors (TLRs) and
their downstream targets, including inﬂammatory cytokines
and chemokines, as emerging factors in the development
of NAFLD. We further review the role of nuclear factor κB
(NF-κB) and c-Jun N-terminal kinase (JNK), key molecules
mediating TLR signaling in NAFLD. Since hepatic resident2 Gastroenterology Research and Practice
macrophages, Kupﬀer cells, perceive various TLR ligands
andproduceinﬂammatory mediators throughNF-κBand/or
JNK activation [9–11], we will focus on TLR signaling in
Kupﬀer cells.
2.The Gut-Liver Axis Is an Important Pathway
inthe DevelopmentofNAFLD
Gut microbiota, consisting of 15,000–35,000 species of bac-
teria, play a crucial role in nutrient absorption and energy
storage [12–14]. Young conventionally reared mice have a
40% higher body fat and 47% higher gonadal fat content
than germ-free mice, even though conventionally reared
mice consume fewer calories. In addition, gnotobiotic mice
exhibit a 60% increase in body fat within 2 weeks following
transplantation of the gut microbiota from conventionally
reared mice [15], indicating that gut microbiota contribute
to nutrient acquisition. In particular, gut microbiota pro-
mote absorption of monosaccharides from the gut lumen,
with resulting induction of de novo hepatic lipogenesis [15].
In addition to nutrient acquisition, gut microbiota are
a source of bacterial products such as lipopolysaccharide
(LPS), bacterial DNA, and peptidoglycan, which are deliv-
ered to the liver through the portal vein. In murine models
of NAFLD, bacterial overgrowth is observed with compo-
sitional change as well as increased intestinal permeability
by reducing the expression of tight junction proteins such
as ZO-1 and occludin [16]. In human, the composition of
gut microbiota diﬀers between individuals with and without
diabetes mellitus [17, 18]. Indeed, circulating bacterial com-
ponents are elevated in NAFLD patients and in animal
models [19–22]. As a result, liver cells are exposed to a high
load of bacterial productsthat function as TLR ligands. Since
TLR signaling is a key pathway to produce inﬂammatory
cytokines and chemokines, the gut microbiota contribute to
the developmentof NAFLD as a source of TLR ligands.
3.TLRsAre AssociatedwithNAFLD
TLRs are associated with liver diseases including alcoholic
liver injury, ischemia/reperfusion liver injury, liver ﬁbrosis,
and liver cancer [23, 24]. Among 13 TLRs identiﬁed in
mammals, TLR2, TLR4, and TLR9 play a role in the devel-
opment of NAFLD [20, 21, 25, 26]. To date, no information
isavailableon theroleofotherTLRsinNAFLD.Resultsfrom
gene-modiﬁed mice indicate that TLR4, and TLR9 signaling
promote the progression of NAFLD.
Several groups have demonstrated that TLR4 signaling
worsens NAFLD [19–21]. TLR4 is the receptor for LPS, a
component of the Gram-negative bacterial cell wall. Serum
LPS levels are increased in patients with hepatic steatosis
caused by total parenteral nutrition or intestinal bypass [27–
29]. Antibioticstreatment in these patients attenuatessteato-
sis with decreased plasma levels of LPS [27–29]. Circulating
LPS levels are elevated in most animal models of NAFLD
induced by diets, including the high-fat (HF) diet, fructose-
rich diet, methionine/choline-deﬁcient (MCD) diet, and
choline-deﬁcient amino acid-deﬁned (CDAA) diet [19–22].
Wild-type (WT) mice fed these diets show severe steatosis or
steatohepatitis. In contrast, TLR4 mutant mice on these
diets have less steatosis or steatohepatitis, although LPS
levels are equivalent to those in WT mice. Even in mice
on standard laboratory chow, continuous subcutaneous
infusion of low-dose LPS results in hepatic steatosis, hepatic
insulin resistance, and hepatic weight gain [30]. In addition,
an intraperitoneal injection of LPS exacerbates liverinjury in
mice fed an MCD diet [31]. Eighty percent of intravenously
injected LPSs molecules are detected in the liver within 20–
30min [32, 33]. These data indicate that the liver is the
main target of LPS, and LPS-TLR4 is a key pathway for the
progression of NAFLD.
TLR9 signaling contributes to the developmentof NASH
[26]. TLR9 recognizes DNA containing an unmethylated-
CpG motif that is highly expressed in bacteria-derived DNA
[34]. Although bacterial DNA is detectable in blood and
ascitesinpatientswithadvancedcirrhosis [35,36],itremains
unclear whether bacterial DNA is present at the early stage
of liver disease and whether bacterial DNA contributes to
NAFLD. We have recently demonstrated that bacterial DNA
is detectable in the blood in a murine model of NASH,
and that bacterial DNA binding to TLR9 contributes to the
development of steatohepatitis [26]. WT mice on a CDAA
diet showed severe steatohepatitis with insulin resistance.
In contrast, TLR9-deﬁcient mice had less steatohepatitis
even though bacterial DNA was present in the blood [26].
In addition, TLR9-deﬁcient mice demonstrated less insulin
resistance and less ﬁbrogenic response [26].
The role of TLR2 in NAFLD has not been well studied.
TLR2 recognizes components of Gram-positive bacterial cell
wall such as peptidoglycan and lipoteichoic acid [34]. At
present, no studies have shown increased TLR2 ligands in
NAFLD, which might be limited by current methodology.
Blockadeof TLR2 signaling prevents insulin resistance in HF
diet-fed mice [37, 38]. In contrast, TLR2-deﬁcient mice on
an MCD diet exhibit equivalent levels of steatohepatitis but
more severe steatohepatitis after LPS challenge compared to
WT mice [25].
MyD88 is a key molecule in the development of
metabolic syndrome including NAFLD [39, 40]. MyD88, an
adaptor protein for all TLRs except for TLR3, is required
for the expression of various inﬂammatory cytokines and
chemokines [41]. MyD88-deﬁcient mice are protected from
metabolic syndrome including atherosclerosis [39, 40]a n d
from liver injury induced by bile duct ligation or carbon
tetrachloride [23, 42]. We have demonstrated that MyD88-
deﬁcient mice on a CDAA diet show less steatohepatitis
with less insulin resistance compared with WT mice [26].
As expected, inﬂammatory cytokines and ﬁbrogenic factors
are also signiﬁcantly suppressed in MyD88-deﬁcient mice
compared with WT mice fed a CDAA diet [26].
4.EndogenousTLRLigandsinNAFLD
Nonbacterial substances may function as TLR ligands; free
fatty acids (FFAs) and denatured host DNA activate TLR2,
TLR4 and TLR9 [43–46]. For instance, palmitate activatesGastroenterology Research and Practice 3
WT macrophage but not TLR4-deﬁcient macrophages [44].
Stearic acid and palmitic acid, potential TLR4 ligands, are
rich in dietary fat, and circulating FFAs are elevated in
patients with NAFLD [47]. These data demonstrate an
association between TLR4 and FFAs. On the other hand,
some reports have demonstrated that FFAs do not bind to
TLR4 [48, 49]. LPS has a high aﬃnity for lipids such as
chylomicrons and fatty acids, suggesting that contaminated
LPS in the lipids may be the actual TLR4 ligand. Although
the LPS-lipids complexes still have aﬃnity to TLR4, the toxic
eﬀectofLPS isdecreased [50, 51]. Thus, the conceptoflipids
as endogenous TLR4 ligands is still unresolved. TLR4 also
recognizesoxidizedphospholipid[52]andHMGB-1[53].To
date, the role of these TLR4 ligands has not been investigated
in NAFLD.
Denatured host DNA is a candidate for a TLR9 ligand
in liver injury. Apoptotic hepatocyte DNA induces type I
collagen and TGFβ expression in hepatic stellate cells via
TLR9 [45]. Denatured host DNA also stimulates sinusoidal
endothelial cells to produce interleukin (IL)-1β via TLR9
[24]. In these studies, TLR9-deﬁcient mice were resistant to
carbon tetrachloride- oracetaminophen-induced sterile liver
injury. If apoptotic host DNA functions as a TLR9 ligand,
NASH livers are constantly exposed to TLR9 ligands because
hepatocytes undergo apoptosis and necrosis in NASH.
However, the unmethylated CpG-motif is uncommon in
mammalian DNAs [54], and host DNA is recognized
by other DNA sensors such as DNA-dependent activator
of IFN-regulatory factors and the inﬂammasome which
sense cytosolic DNA in TLR9-indendent manner [55, 56].
Although some FFAs and denatured host DNA are attractive
candidates for TLR ligands, further investigations are nec-
essary to determine whether these nonbacterial substances
function as reliable TLR ligands in NAFLD.
5.LiverCellsThatPerceiveTLRLigands
The liver is composed of various types of cells including
hepatocytes, biliary epithelial cells, hepatic stellate cells,
Kupﬀer cells, and sinusoidal endothelial cells. Most types of
liver cells are reported to express TLRs and produce various
inﬂammatory mediators in response to TLR ligands [10].
For instance, hepatic stellate cells and sinusoidal endothelial
cells produce chemokines and inﬂammatory cytokines in
response to a TLR4 ligand [23] and a TLR9 ligand [24],
respectively. Among resident liver cells, Kupﬀer cells are well
documented to respond to various TLR ligands such as
peptidoglycan, double-stranded RNA, LPS, bacterial DNA,
and probably other TLR ligands. In addition, Kupﬀer cells
are a major source of inﬂammatory cytokines such as TNFα
and IL-1β [9, 11]. These cytokines produced by Kupﬀer cells
promote lipid accumulation and cell death in hepatocytes
as described below in detail. These cytokines also induce
hepatic stellate cells to produce proﬁbrogenic factors such
as TIMP1 and PAI-1 [26, 57, 58]. Thus, Kupﬀer cell-
derived mediators through TLRs aﬀect lipid metabolism,
liver damage and liver ﬁbrosis in NAFLD (Figure 1). Indeed,
depletion of Kupﬀer cells ameliorates the progression of
diet-induced steatohepatitis. Rivera et al. have reported
Kupﬀercell depletiondelayed the developmentof steatohep-
atitis induced by an MCD diet [20]. We also have shown that
depletion of Kupﬀer cells decreased inﬂammatory cytokines
in mice on a CDAA diet, resulting in improvement of
NASH [26]. These ﬁndings indicate that Kupﬀer cells play
a pivotal role in the development of steatohepatitis. On the
other hand, the roles of Kupﬀer cells in HF diet models,
a simple steatosis model, are more complicated. While
most of reports have shown that depletion of Kupﬀer cells
ameliorates steatosis [59–62], one report shows an opposite
eﬀect [63]. This discrepancy may partially depend on the
methodology to deplete Kupﬀer cells. Clodronate liposome
was used to deplete Kupﬀer cells by intravenous injec-
tion [61] or intraperitoneal injection [62, 63]. Intravenous
injection selectively depletes Kupﬀer cells and/or splenic
macrophages but not visceral fat macrophages whereas
intraperitoneal injection aﬀects both Kupﬀer cells and vis-
ceral fat macrophages [23, 64]. Adipose tissue macrophages
are activated in an HF diet model [63] and release various
mediators such as TNFα and IL-6, which inﬂuence insulin
signaling and lipid metabolism. These mediators could
further activate Kupﬀer cells, and contribute to steatosis.
Although further studies are necessary to determine the
role of adipose tissue macrophages in the development of
NAFLD, it is clear that Kupﬀer cells are important in the
development of NAFLD.
6.NF-κBA cti vationinN AFLD
Activation of the transcriptional factor NF-κB, a down-
stream target for TLR-MyD88 signaling, is crucial for the
inﬂammatory response in immune cells and is a key in
the development of NAFLD [10, 11]. In NAFLD patients
as well as animal models of NAFLD, NF-κBa c t i v a t i o n
is observed in liver cells, including hepatocytes, hepatic
stellate cells and Kupﬀer cells [23]. Hepatocytes respond
minimally to TLR ligands in vivo, suggesting that other
mediators activate NF-κB in hepatocytes [23, 65]. For
instance, TNFα and IL-1β activate NF-κB in hepatocytes
[26, 66]. On the other hand, TLR ligands directly activate
NF-κBi nK u p ﬀer cells. TLR signaling triggers inﬂammatory
cytokineand chemokine productionin Kupﬀercells through
NF-κBa c t i v a t i o n[ 26, 67]. IKKβ activates NF-κBb yt h e
phosphorylation and subsequent degradation of Iκ-B, an
essential inhibitor for NF-κB. Speciﬁc deletion of IKKβ in
myeloid cells including macrophages results in suppression
of inﬂammatory cytokine production, which prevents sys-
temic insulin resistance induced by an HF diet [68].
It is unclear whether NF-κB activation in hepatocytes
leads to steatosis. Hepatocyte-speciﬁc IKKβ overexpression
induces steatosis [69]. In contrast, NF-κB essential mod-
ulator (NEMO) deﬁciency in hepatocytes results in spon-
taneous steatohepatitis [70]. NEMO deﬁciency completely
blocks NF-κB activation, indicating that NF-κBa c t i v a t i o n
in hepatocytes is not a primary cause of steatosis. We and
others have recently demonstrated that hepatocytes increase
their lipid content in response to TNFα and IL-1β [26, 71].4 Gastroenterology Research and Practice
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Figure 1: TLRs and downstream signaling in NAFLD. Kupﬀer cells respond to TLR ligands such as LPS and bacterial DNA through TLR4
and TLR9, respectively. Upon TLR ligation, MyD88, an adaptor molecule, is recruited to transmit the signals that activate NF-κBa n d
JNK. Activated Kupﬀer cells produce inﬂammatory cytokines such as TNFα and IL-1β and chemokines such as MCP-1 (CCL2). These
inﬂammatory cytokines and chemokines induce lipid accumulation in hepatocytes and cell death. In addition, TNFα and IL-1β promote
liver ﬁbrosis by activating hepatic stellate cells. Other cells including hepatic resident cells, inﬁltrated cells into the liver, and adipose tissue
macrophages produce various mediators in response to TLR ligands. These pathways also contribute to the development of NAFLD.
In that process, TNFα and IL-1β activate NF-κBi nn o r m a l
hepatocytes. On the other hand, NF-κBa c t i v a t i o nb yT N F α
and IL-1β is blunted in lipid-laden hepatocytes [26]. NF-κB
activation in hepatocytes may be required only for an initial
step of lipid accumulation in the liver. Regardless of NF-κB
activation in hepatocytes, inﬂammatory cell inﬁltrations and
expression of F4/80, a marker for macrophage, are increased
in both hepatocyte-speciﬁc IKKβ overexpressed mice and
hepatocyte-speciﬁc NEMO-deﬁcient mice [69, 70]. These
data further support the concept that NF-κBa c t i v a t i o ni n
immune cells is a key event in the development of NAFLD.
7.JNKActivationinNAFLD
TLR-MyD88 signaling pathway activates JNK, a member of
mitogen-activated proteinkinases. JNKis an attractive target
in the pathogenesis of NAFLD, because JNK activation plays
a central role in the developmentofobesity and insulin resis-
tance [72]. In patients and animals with NASH, JNK is acti-
vated in the liver, and JNK activation in immune cells results
in inﬂammatory cytokine production [22]. Current research
is analyzing the distinct roles of the JNK isoforms, JNK1 and
JNK2,inthedevelopmentofthemetabolicsyndromeinclud-
ing NAFLD. JNK1 promotes steatosis and inﬂammation in
two diﬀerent models of NAFLD [73]. In contrast, lack of
JNK2 promotes liver injury [74]. However, it must be noted
thattherolesofJNKsarediﬀerentinhepatocytesandKupﬀer
cells; JNK activation in hepatocytes is involved in cell death
and insulin signaling whereas JNK activation in Kupﬀercells
inducesinﬂammatory cytokineproduction.Recently,weand
others have demonstrated the role of hematopoietic cells
in the development of the metabolic syndrome including
NASH [22, 75]. The results from chimeric mice generated
by transplanting bone marrow cells lacking JNK1 or JNK2
into WT mice have shown that JNK1 in hematopoietic cellsGastroenterology Research and Practice 5
contributes to developingmetabolic syndrome by producing
inﬂammatory cytokines. Thus, hematopoietic cellsincluding
Kupﬀer cells and recruited macrophages play a pivotal role
in the development of NAFLD. On the other hand, JNK in
hepatocytes is involved in cell death and insulin signaling.
Thus, JNK plays multiple roles in multiple steps in NAFLD.
8. Inﬂammatory Cytokinesand NAFLD
Inﬂammatory cytokines are important mediators in the
development of NAFLD. Among inﬂammatory cytokines,
TNFα and IL-1β have multiple functions including immune
modulation,celldiﬀerentiation,proliferation,apoptosis,and
energy metabolism. Indeed, expressions of TNFα and IL-1β
are increased in NAFLD patients and animal models [76–
79]. In contrast, most of TLR-deﬁcient mice show decreased
TNFα and IL-1β levels in NAFLD models [20, 26].
TNFα levels are increased in the liver, the adipose tissue,
and the serum of NAFLD patients [76, 77]. Expression
of TNF receptors is also increased in the liver of NAFLD
patients[77].Micedeﬁcientin bothTNFreceptortype1and
type 2 demonstrate less steatosis, inﬂammation, and liver
ﬁbrosis in a NASH diet model [80], indicating that TNF
receptorsignalingcontributestothedevelopmentofNAFLD.
So far, several mechanisms of TNFα-mediated functions are
proposed: (1) insulin resistance, (2) release of fatty acids
from adipose tissue, (3) regulation of lipid inﬂux and eﬄux
in hepatocytes, and (4) hepatocyte cell death. TNFα impairs
insulin signaling by suppressing insulin receptors, insulin
receptor substrate-1 and GLUT4 expressions [80], and by
the expression of SOCS-3. As a result of insulin resistance,
FFAsand glucose uptakeare inhibited in adipocytes, whereas
increased insulin levels promote FFA ﬂux into hepatocytes
and hepatic lipogenesis [81]. Moreover, TNFα increases fatty
acid release from adipose tissue by promoting lipolysis,
resultingininsulinresistance.Inadditiontoimpairedinsulin
signaling and FFA metabolism, TNFα promotes cholesterol
accumulation in hepatocytes by inducing expression of
LDL receptor and by inhibiting eﬄux of cholesterol [71].
Thus, TNFα promotes lipid accumulation in hepatocytes
inducing insulin resistance, increased FFA levels, and lipid
retention in the cells. Lipid-accumulated hepatocytes are
vulnerable to various stimuli such as TNFα.I nN A S H
patients, hepatocyte apoptosis and necrosis frequently occur.
TNFαstimulationalonedoesnotinducecelldeathinnormal
hepatocytes, because TNFα induces the upregulation of NF-
κB-related antiapoptoticgenes[66]. However, impaired lipid
metabolism leads to hepatocyte apoptosis in the presence
of TNFα. Hepatocytes laden with lipids have increased sus-
ceptibility to TNFα-induced cell death [82, 83]. Free choles-
terol accumulation in hepatocytes depletes mitochondrial
glutathione. This induces ROS generation in hepatocytes
and then evokes cell death signaling [82]. In addition, lipid-
accumulated hepatocytes increase the expression of ASK-1
and JNK in response to TNFα [83], which lead to cell death.
These ﬁndings demonstrate that TNFα plays an important
role in lipid metabolism as well as hepatocyte cell death in
the developmentof NAFLD.
Increased IL-1β is recognized as a risk factor for the
metabolicsyndrome [84].Indeed,expressionofIL-1β aswell
as its receptor is increased in the adipose tissue of obese
patients with type II diabetes [78, 79]. Single-nucleotide
polymorphisms of IL-1β,w h i c hm a ye l e v a t ec i r c u l a t i n g
IL-1β, are frequently observed in patients with metabolic
syndrome including atherosclerosis [85, 86]a n dN A S H[ 87].
Inadditiontotheseﬁndings, blockadeofIL-1β decreasedthe
severity of atherosclerosis and insulin sensitivity in animal
models [88, 89]. HF diet feeding, a diet model for obesity
and hepatic steatosis, results in severe steatohepatitis in IL-
1 receptor antagonist-deﬁcient mice [90], suggesting that
IL-1β plays an important role in NASH. The proposed
functions of IL-1β are as follows: (1) lipid accumulation in
hepatocytes [26, 71], (2) hepatocyte cell death [26], and (3)
activationofhepaticstellatecells[26,57,58].IL-1βpromotes
hepatic steatosis by activating PPARα [62]a n dd i a c y l g l y c e r o l
acyltransferase 2, an enzyme that converts diglyceride to
triglyceride [26]. In addition, IL-1β promotes cell death
in lipid-accumulated hepatocytes. Upon IL-1β stimulation,
antiapoptotic genes are upregulated in normal hepatocytes.
In contrast, proapoptotic genes such as Bax are induced
in lipid-accumulated hepatocytes treated with IL-1β [26].
IL-1β induces the production of nitric oxide, generating
peroxynitrite in the presence of superoxide radicals, which
induces hepatocellular injury. In NAFLD, free radicals are
generated by β-peroxidation of FFAs, and nitric oxide
m eta boli t esa r ei n cr ea s edi nra tswi thN ASH[91],which may
further promote liver injury. Moreover, IL-1β contributes to
liver ﬁbrosis by activating hepatic stellate cells [26, 57, 58].
IL-1β inducesthe expression ofTIMP-1 and TGFβ in hepatic
stellate cells. We have shown that IL-1R-deﬁcient mice are
resistant to CDAA diet-induced liver ﬁbrosis [26]. Thus, IL-
1β is an important factor in the development of NAFLD.
9.Chemokinesand NAFLD
Chemokines, strongly induced by TLR stimulation, play
an important role in the development of metabolic syn-
drome includingNAFLD.TLR4- and MyD88-deﬁcient mice,
which are resistant to metabolic syndrome, show reduced
chemokine production compared with WT mice [39, 40].
MCP-1 levels are elevated in genetically obese diabetic
(db/db) mice and in HF diet-fed mice. This suggests that
MCP-1 and its receptor CCR2 contribute to the meta-
bolic syndrome including obesity-related steatosis [92–
95]. Indeed, MCP-1 overexpressing transgenic mice exhibit
insulin resistance and hepatic steatosis as well as macrophage
inﬁltration in adipose tissue. In contrast, MCP-1- or CCR2-
deﬁcient mice have attenuated HF diet-induced steatosis
and macrophage inﬁltration. In these mice, inﬂammatory
cytokine production is reduced, which could ameliorate
steatohepatitis. Moreover, administration of a CCR2 antago-
nist improves insulin resistance. Clinical studies also demon-
strate that MCP-1 levels in adipose tissue positively correlate
with BMI, and patients with type II diabetes have higher
serum MCP-1 levels than nondiabetes [96].6 Gastroenterology Research and Practice
In addition to macrophage recruitment, MCP-1 pro-
motes hepatic lipid accumulation by increasing lipid synthe-
sisandbyinhibitinglipideﬄuxfromhepatocytes[97].MCP-
1 increases PEPCK level, resulting in de novo lipogenesis.
MCP-1 decreases secretion of ApoB, which suppresses lipid
eﬄux. Since hepatocytes do not express CCR2, hepatocytes
may utilize other receptors such as CCR7 and CCR8 as
the receptors for MCP-1. Thus, MCP-1 regulates lipid
metabolism through macrophage recruitment and also di-
rectly on hepatocytes.
10.Perspectives
This paper summarized the role of TLRs and their down-
stream moleculesin the developmentofNAFLDand showed
that TLR signaling mediates steatosis, inﬂammation, and
ﬁbrosis. Thus, regulation of TLRs and their downstream
molecules is potential targets for the therapy of NAFLD, in
particular NASH. Several antagonists for TNFα,I L - 1 β,a n d
CCR2areusedinNAFLDanimal models[89,93,98–101].In
the future, these agents may be new tools for the therapy of
humanNAFLD.InadditiontotheblockadeofTLRsignaling,
control of TLR ligands is another option for the therapy
of NAFLD. Probiotics may suppress the growth of harmful
intestinal bacteria and the generation of TLR ligands in
the intestine. As a result, exposure to TLR ligands may be
decreased in the liver. Beneﬁcial eﬀects of probiotics have
beenreported inanimal NAFLDmodels[98,102,103].Since
their adverse eﬀects are minimal in humans, randomized
clinical trials of adequate size and methodology are needed
for assessing the beneﬁt of using probiotics on the NAFLD
patients.
TLRs play multiple roles in multiple steps and in many
hepatic cells in the development of NAFLD. In this review,
wefocusedontheTLRsignaling inKupﬀercellsthatproduce
key mediators in NAFLD. Other resident liver cells and
recruited immune cells also produce many mediators that
modulate the status of NAFLD in response to TLR ligands
(Figure 1). Thus, better understanding of TLR signaling will
provide new insight into the management and prevention of
NAFLD.
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